<--- Back to Details
First PageDocument Content
Immunosuppressants / Autoimmune diseases / Natalizumab / Cytokines / Multiple sclerosis / Progressive multifocal leukoencephalopathy / JC virus / Rituximab / Interferon beta-1a / Medicine / Health / Immunology
Date: 2013-06-09 23:17:10
Immunosuppressants
Autoimmune diseases
Natalizumab
Cytokines
Multiple sclerosis
Progressive multifocal leukoencephalopathy
JC virus
Rituximab
Interferon beta-1a
Medicine
Health
Immunology

What’s “hot” about thermogenic agents

Add to Reading List

Source URL: dpic.org

Download Document from Source Website

File Size: 67,75 KB

Share Document on Facebook

Similar Documents

Cytokines / Interferon beta-1a / Lifeline / TTY / Glatiramer acetate

PDF Document

DocID: 1rhTx - View Document

Specialty drugs / Health maintenance organizations / Medicinal chemistry / Pharmacy / Blue Cross Blue Shield Association / Specialty pharmacy / Interferon beta-1a / Biology / Health / Medicine

Blue Cross Blue Shield of Wyoming Prime Therapeutics Specialty Pharmacy Drug Management List Definition of specialty medications: Specialty medications are generally prescribed for people with complex or ongoing medical

DocID: 1r7Ye - View Document

Medicine / Medical research / Immunology / Clinical research / Multiple sclerosis / Immunosuppressants / Design of experiments / Medical ethics / Fingolimod / Management of multiple sclerosis / Interferon beta-1a / Clinical trial

Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio

DocID: 1qn6Z - View Document

Cytokines / Interferon beta-1a / Glatiramer acetate / Natalizumab

PDF Document

DocID: 1ptj0 - View Document

Cytokines / PEGylation / Schering AG / Interferon beta-1b / Interferon / Polyethylene glycol / Management of multiple sclerosis / Multiple sclerosis / Interferon beta-1a / Enzon Pharmaceuticals

MOUNTAIN VIEW PHARMACEUTICALS

DocID: 1oFr0 - View Document